The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia.
BACKGROUND
Pathology of dorsolateral prefrontal cortex and dysregulation of dopaminergic neurons have been associated with the pathophysiology of schizophrenia, but how these phenomena relate to each other in patients has not been known. It has been hypothesized that prefrontal cortical pathology might induce both diminished steady-state and exaggerated responses of dopaminergic neurons to certain stimuli (e.g., stress). We examined the relationship between a measure of prefrontal neuronal pathology and striatal dopamine activity in patients with schizophrenia and in a nonhuman primate model of abnormal prefrontal cortical development.


METHODS
In the patients, we studied in vivo markers of cortical neuronal pathology with NMR spectroscopic imaging and of steady-state striatal dopamine activity with radioreceptor imaging. In the monkeys, we used the same NMR technique and in vivo microdialysis.


RESULTS
Measures of N-acetyl-aspartate concentrations (NAA) in dorsolateral prefrontal cortex strongly and selectively predicted D2 receptor availability in the striatum (n = 14, rho = -.64, p < .01), suggesting that the greater the apparent dorsolateral prefrontal cortex pathology, the less the steady-state dopamine activity in these patients. A similar relationship between NAA measures in dorsolateral prefrontal cortex and steady-state dopamine concentrations in the striatum was found in the monkeys (n = 5, rho = .70, p < .05). We then tested in the same monkeys the relationship of prefrontal NAA and striatal dopamine overflow following amphetamine infusion into dorsolateral prefrontal cortex. Under these conditions, the relationship was inverted, i.e., the greater the apparent dorsolateral prefrontal cortex pathology, the greater the dopamine release.


CONCLUSIONS
These data demonstrate direct relationships between putative neuronal pathology in dorsolateral prefrontal cortex and striatal dopamine activity in human and nonhuman primates and implicate a mechanism for dopamine dysregulation in schizophrenia.
Bertolino
A
A
Clinical Brain Disorders Branch, National Institute of Mental Health, NIH Bethesda, MD 20892, USA.
Knable
M B
MB
Saunders
R C
RC
Callicott
J H
JH
Kolachana
B
B
Mattay
V S
VS
Bachevalier
J
J
Frank
J A
JA
Egan
M
M
Weinberger
D R
DR
D000328:Adult; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism*; D002794:Choline / Q000378:metabolism; D002908:Chronic Disease; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D008253:Macaca mulatta; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D009474:Neurons / Q000502:physiology; D017397:Prefrontal Cortex / Q000378:metabolism*; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012559:Schizophrenia / Q000175:diagnosis / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon
D017448:Receptors, Dopamine D2; D001224:Aspartic Acid; D003404:Creatinine; D002794:Choline; D004298:Dopamine